Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Hou, Zhi duo ^a   Xiao, Zheng yu ^a   Gong, Yao ^a   Zhang, Yu ping ^a   Zeng, Yu ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Adverse drug reactions; Ankylosing spondylitis; Arylamine N acetyltransferases; Genetic polymorphism; Sulfasalazine

Indexed keywords

AMINOTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 1; ARYLAMINE N ACETYLTRANSFERASE 2; GENOMIC DNA; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACETYLATOR GENOTYPE; ADULT; ALLELE; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTICLE; CACOSPERMIA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; GENE FREQUENCY; GENOTYPE; HAN CHINESE; HETEROZYGOTE; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; LEUKOPENIA; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEMEN ABNORMALITY; WILD TYPE; ADVERSE DRUG REACTION; AMINOTRANSFERASE BLOOD LEVEL; DISEASE DURATION; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; GENE; GENETIC POLYMORPHISM; NAT1 GENE; NAT2 GENE; RASH; SIDE EFFECT; TREATMENT WITHDRAWAL;

EID: 84924357678     PISSN: 20506511     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-64.     Document Type: Article

References (43)

1. Zeng QY: Ankylosing spondylitis in Shantou, China: 15 years' clinical experience. J Rheumatol 2003,30(8):1816-1821.
2. Dougados M, Maetzel A, Mijiyawa M, Amor B: Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis 1992,51(8):955-958.10.1136/ard.51.8.955.
3. Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999,42(11):2325-2329.10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C.
4. Schmidt WA, Wierth S, Milleck D, Droste U, Gromnica-Ihle E: Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. Z Rheumatol 2002,61(2):159-167.10.1007/s003930200024.
5. Taggart AGP, McEvoy FHR, Bird H: Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum 1996,39(8):1400-1405.10.1002/art.1780390819.
6. Tanigawara Y, Kita T, Aoyama N, Gobara M, Komada F, Sakai T, Kasuga M, Hatanaka H, Sakaeda T, Okumura K: N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002,25(8):1058-1062.10.1248/bpb.25.1058.
7. Moum B: Which are the 5-ASA compound side effects and how is it possible to avoid them. Inflamm Bowel Dis 2008,14(Suppl 2):S212-S213.
8. Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugsof 5-aminosalicylic acid. Clin Pharmacokinet 1985,10(4):285-302.10.2165/00003088-198510040-00001.
9. Plosker GL, Croom KF: Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005,65(13):1825-1849.10.2165/00003495-200565130-00008.
10. Kuhn UD, Anschutz M, Schmucker K, Schug BS, Hippius M, Blume HH: Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther 2010,48(1):1-10.10.5414/CPP48001.
11. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995,5(1):1-17.10.1097/00008571-199502000-00001.
12. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B: Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 2009,12(5-6):440-472.
13. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269-296.10.1146/annurev.pharmtox.37.1.269.
14. Hein DW: N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understandingcomplexities of personalized medicine. Expert Opin Drug Metab Toxicol 2009,5(4):353-366.10.1517/17425250902877698.
15. Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B, Brzosko M, Dabrowska-Zamojcin E: Increased genotype frequency of N-acetyltransferase 2 slow acetylation inpatients with rheumatoid arthritis. Clin Pharmacol Ther 2002,72(3):319-325.10.1067/mcp.2002.126740.
16. Baranska M, Trzcinski R, Dziki A, Rychlik-Sych M, Dudarewicz M, Skretkowicz J: The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease. Dig Dis Sci 2011,56(7):2073-2080.10.1007/s10620-010-1527-4.
17. Mikuls TR, Levan T, Gould KA, Yu F, Thiele GM, Bynote KK, Conn D, Jonas BL, Callahan LF, Smith E, Brasington R, Moreland LW, Reynolds R, Gaffo A, Bridges SL Jr: Interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. Arthritis Rheum 2012,64(3):655-664.10.1002/art.33408.
18. Tamer L, Tursen U, Eskandari G, Ates NA, Ercan B, Yildirim H, Atik U: N-acetyltransferase 2 polymorphisms in patients with Behcet's disease. Clin Exp Dermatol 2005,30(1):56-60.10.1111/j.1365-2230.2004.01685.x.
19. Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Takahashi H, Kobashi G, Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupuserythematosus in a Japanese population. Lupus 2009,18(7):630-638.10.1177/0961203309102809.
20. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B: Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997,36(10):1089-1094.10.1093/rheumatology/36.10.1089.
21. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005,366(9486):649-659.10.1016/S0140-6736(05)67137-1.
22. Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC: NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2010,123(3):877-883.10.1007/s10549-010-0807-1.
23. Butcher NJ, Minchin RF: Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev 2012,64(1):147-165.10.1124/pr.110.004275.
24. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC: Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995,55(16):3537-3542.
25. Kita T, Sakaeda T, Adachi S, Sakai T, Aoyama N, Hatanaka H, Kasuga M, Okumura K: N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol Pharm Bull 2001,24(10):1176-1180.10.1248/bpb.24.1176.
26. Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K: N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in patients with Rheumatoid Arthritis. Pharm Res 2004,21(2):324-329.
27. Chen B, Zhang WX, Cai WM: The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol 2006,62(5):355-359.10.1007/s00228-006-0110-6.
28. Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X: Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta 2009,407(1-2):30-35.
29. Daly AK: Pharmacogenomics of adverse drug reactions. Genome Med 2013,5(1):5.10.1186/gm409.
30. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984,27(4):361-368.10.1002/art.1780270401.
31. Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z: N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 2007,21(3):155-158.
32. Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N: Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 2004,18(2):233-247.10.1016/j.berh.2004.02.006.
33. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000,356(9237):1255-1259.10.1016/S0140-6736(00)02799-9.
34. Cascorbi I, Roots I, Brockmoller J: Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001,61(13):5051-5056.
35. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B: Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011,63(6):1543-1551.10.1002/art.30223.
36. Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B: Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986,293(6544):420-423.10.1136/bmj.293.6544.420.
37. Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N: Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002,29(12):2492-2499.
38. Soejima M, Kawaguchi Y, Hara M, Kamatani N: Prospective study of the association between NAT2 gene haplotypes and severeadverse events with sulfasalazine therapy in patients with rheumatoid arthritis. J Rheumatol 2008,35(4):724.
39. Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F: NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoidlupus erythematosus. Pharmacogenetics 1997,7(2):131-135.10.1097/00008571-199704000-00006.
40. Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ: N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002,97(7):1763-1768.10.1111/j.1572-0241.2002.05838.x.
41. Kitas GD, Farr M, Waterhouse L, Bacon PA: Influence of acetylator status on sulphasalazine efficacy and toxicity inpatients with rheumatoid arthritis. Scand J Rheumatol 1992,21(5):220-225.10.3109/03009749209099228.
42. Wang D, Para MF, Koletar SL, Sadee W: Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics 2011,21(10):652-664.10.1097/FPC.0b013e3283498ee9.
43. Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, Yan XD, Huang SL, Wang W, Zhou HH: Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997,7(6):503-514.10.1097/00008571-199712000-00009.